Your skin,
in sequence.
Skin has patterns. SEQUEN finds them. The first platform that shows you what is actually changing your skin, over time.
FOUNDING ACCESS · CLOSES AT 500 · NO PLEDGE REQUIRED
People invest in their skin blind.
The average woman buys six new skincare products a year and abandons 40% within 90 days. That is about $313 spent with no way to know which $313 worked. And it is no longer just women: 52% of U.S. men now use facial skincare. Dermatologists, meanwhile, see patients every three to six months, with no standardized imaging in between.
Everyone spends. No one measures.
SOURCES: NPD CIRCANA 2024 · MINTEL 2024 · ALLURE 2022
Between dermatology visits, with no record kept in between.
Objective longitudinal skin data in the hands of the person who owns the skin.
Measure. Score. Connect.
A standardized record of your skin, built from guided scans and scored against your own baseline, never anyone else's.
Guided, standardized scans
Consistent lighting and angles every time, so this month's scan is comparable to last month's.
Six conditions, scored
Acne, redness, pigmentation, texture, barrier, and aging, anchored to the clinical scales used in dermatology trials.
Connected to your biology
Skin change linked to cycle phase, sleep, treatments, ingredients, and environment, against your own baseline.
Observational, never diagnostic. SEQUEN supplements professional care, it doesn't replace it.
Your skin runs on your hormones.
Cycle apps know your phase. Skincare apps know your products. Neither connects them to your skin. SEQUEN tracks skin change across the cycle, and through perimenopause, menopause, HRT, and TRT.
- +Phase-aware skin guidance, from follicular glow to luteal congestion
- +Sleep, recovery, and body temperature context via HealthKit and Oura
- +Built for every body: cycling, postmenopausal, on HRT, on TRT
Every ingredient, down to the molecule.
Scan any label. SEQUEN reads the full ingredient list and checks it against NIH molecular data: photosensitivity flags, synthetic polymer detection, ingredient conflicts, and how each active behaves on skin.
90+ actives and 35 medications, mapped to their molecules.
Built to a clinical standard.
Not another beauty filter. A measurement instrument, held to the standards instruments are held to.
Scores anchored to IGA, Glogau, CEA, and mMASI, the scales used in dermatology trials.
Fitzpatrick I through VI calibration as a foundational capability, not an afterthought.
Developed with dermatology and medical advisors guiding scale anchoring and validation.
Observational language enforced at the model layer. SEQUEN describes, it never diagnoses.
Your data stays yours. Private by architecture, exportable always, deletable forever.
500 seats. Then it closes.
Founding members lock the lowest rate SEQUEN will ever offer, and keep it for as long as they stay subscribed. When the 500 seats are gone, founding access closes for good.
NO PLEDGE REQUIRED · LAUNCHING SUMMER 2026